Vicarious Surgical (RBOT) Competitors

$0.95 +0.07 (+7.84%)

As of 03:46 PM Eastern

RBOT vs. IINN, HIND, SURG, MBAI, and ALUR

Should you buy Vicarious Surgical stock or one of its competitors? MarketBeat compares Vicarious Surgical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vicarious Surgical include Inspira Technologies OXY B.H.N. (IINN), Vyome (HIND), SurgePays (SURG), Check-Cap (MBAI), and Allurion Technologies (ALUR). These companies are all part of the "medical equipment" industry.

How does Vicarious Surgical compare to Inspira Technologies OXY B.H.N.?

Vicarious Surgical (NYSE:RBOT) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Inspira Technologies OXY B.H.N. has higher revenue and earnings than Vicarious Surgical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Inspira Technologies OXY B.H.N.	$289K	48.69	-$13.22M	N/A	N/A

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. 9.5% of Vicarious Surgical shares are owned by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Inspira Technologies OXY B.H.N. had 6 more articles in the media than Vicarious Surgical. MarketBeat recorded 6 mentions for Inspira Technologies OXY B.H.N. and 0 mentions for Vicarious Surgical. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.33 beat Vicarious Surgical's score of 0.00 indicating that Inspira Technologies OXY B.H.N. is being referred to more favorably in the news media.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Inspira Technologies OXY B.H.N.	Neutral

Vicarious Surgical presently has a consensus price target of $7.00, suggesting a potential upside of 637.62%. Inspira Technologies OXY B.H.N. has a consensus price target of $2.00, suggesting a potential upside of 410.99%. Given Vicarious Surgical's higher probable upside, equities analysts plainly believe Vicarious Surgical is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vicarious Surgical has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

Summary

Inspira Technologies OXY B.H.N. beats Vicarious Surgical on 10 of the 12 factors compared between the two stocks.

How does Vicarious Surgical compare to Vyome?

Vyome (NASDAQ:HIND) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Vyome has higher revenue and earnings than Vicarious Surgical. Vyome is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	48.92	-$10.26M	-$12.27	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Vicarious Surgical has a net margin of 0.00% compared to Vyome's net margin of -270.58%. Vicarious Surgical's return on equity of -184.13% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-203.92%	-134.16%
Vicarious Surgical	N/A	-184.13%	-112.50%

In the previous week, Vyome had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 1 mentions for Vyome and 0 mentions for Vicarious Surgical. Vyome's average media sentiment score of 0.00 equaled Vicarious Surgical'saverage media sentiment score.

Company	Overall Sentiment
Vyome	Neutral
Vicarious Surgical	Neutral

22.1% of Vyome shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 33.0% of Vyome shares are held by insiders. Comparatively, 9.5% of Vicarious Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vyome has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Vyome presently has a consensus price target of $15.00, suggesting a potential upside of 572.65%. Vicarious Surgical has a consensus price target of $7.00, suggesting a potential upside of 637.62%. Given Vicarious Surgical's higher probable upside, analysts plainly believe Vicarious Surgical is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Vicarious Surgical beats Vyome on 8 of the 14 factors compared between the two stocks.

How does Vicarious Surgical compare to SurgePays?

SurgePays (NASDAQ:SURG) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

SurgePays has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

SurgePays has higher revenue and earnings than Vicarious Surgical. SurgePays is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.22	-$36.07M	-$1.94	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

6.9% of SurgePays shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 9.5% of Vicarious Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, SurgePays had 5 more articles in the media than Vicarious Surgical. MarketBeat recorded 5 mentions for SurgePays and 0 mentions for Vicarious Surgical. Vicarious Surgical's average media sentiment score of 0.00 beat SurgePays' score of -0.28 indicating that Vicarious Surgical is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Neutral
Vicarious Surgical	Neutral

Vicarious Surgical has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. Vicarious Surgical's return on equity of -184.13% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-290.44%
Vicarious Surgical	N/A	-184.13%	-112.50%

SurgePays presently has a consensus price target of $5.00, suggesting a potential upside of 880.20%. Vicarious Surgical has a consensus price target of $7.00, suggesting a potential upside of 637.62%. Given SurgePays' higher possible upside, research analysts plainly believe SurgePays is more favorable than Vicarious Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

SurgePays and Vicarious Surgical tied by winning 7 of the 14 factors compared between the two stocks.

How does Vicarious Surgical compare to Check-Cap?

Vicarious Surgical (NYSE:RBOT) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 9.5% of Vicarious Surgical shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Check-Cap had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for Vicarious Surgical. Vicarious Surgical's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Check-Cap	Neutral

Check-Cap's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Check-Cap	N/A	N/A	N/A

Vicarious Surgical has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Check-Cap is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

Vicarious Surgical currently has a consensus target price of $7.00, suggesting a potential upside of 637.62%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, equities analysts clearly believe Vicarious Surgical is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Vicarious Surgical beats Check-Cap on 6 of the 11 factors compared between the two stocks.

How does Vicarious Surgical compare to Allurion Technologies?

Vicarious Surgical (NYSE:RBOT) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Allurion Technologies has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Allurion Technologies	$17.21M	0.69	-$7.20M	-$10.56	N/A

Vicarious Surgical has a net margin of 0.00% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Allurion Technologies	-199.96%	N/A	-77.13%

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 9.5% of Vicarious Surgical shares are owned by company insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vicarious Surgical presently has a consensus target price of $7.00, indicating a potential upside of 637.62%. Allurion Technologies has a consensus target price of $3.00, indicating a potential upside of 279.75%. Given Vicarious Surgical's higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Allurion Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vicarious Surgical has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market.

In the previous week, Vicarious Surgical's average media sentiment score of 0.00 equaled Allurion Technologies'average media sentiment score.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Allurion Technologies	Neutral

Summary

Allurion Technologies beats Vicarious Surgical on 7 of the 13 factors compared between the two stocks.

Get Vicarious Surgical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RBOT vs. The Competition

Export

Metric	Vicarious Surgical	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$6.76M	$6.98B	$6.34B	$23.04B
Dividend Yield	N/A	1.70%	2.80%	4.13%
P/E Ratio	-0.10	50.13	20.94	30.13
Price / Sales	N/A	72.24	521.14	91.39
Price / Cash	N/A	24.40	43.18	24.44
Price / Book	0.12	6.51	9.98	4.70
Net Income	-$63.22M	$158.81M	$3.55B	$1.07B
7 Day Performance	35.57%	2.22%	0.42%	0.11%
1 Month Performance	35.19%	-0.75%	-0.05%	0.20%
1 Year Performance	-86.74%	2.02%	35.06%	28.02%

Vicarious Surgical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RBOT Vicarious Surgical	N/A	$0.95 +7.8%	$7.00 +637.6%	-88.0%	$6.76M	N/A	N/A	210
IINN Inspira Technologies OXY B.H.N.	1.926 of 5 stars	$0.42 +2.8%	$2.00 +378.5%	-23.7%	$15.03M	$289K	N/A	20	Gap Up
HIND Vyome	2.638 of 5 stars	$1.98 +0.5%	$15.00 +657.6%	N/A	$13.90M	$320K	N/A	50	Positive News
SURG SurgePays	2.415 of 5 stars	$0.54 -2.7%	$5.00 +819.1%	-84.3%	$13.67M	$56.96M	N/A	40	Earnings Report Gap Down
MBAI Check-Cap	0.2388 of 5 stars	$1.69 +6.3%	N/A	N/A	$12.32M	N/A	N/A	80	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RBOT) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vicarious Surgical (RBOT) Competitors

RBOT vs. IINN, HIND, SURG, MBAI, and ALUR

How does Vicarious Surgical compare to Inspira Technologies OXY B.H.N.?

Summary

How does Vicarious Surgical compare to Vyome?

Summary

How does Vicarious Surgical compare to SurgePays?

Summary

How does Vicarious Surgical compare to Check-Cap?

Summary

How does Vicarious Surgical compare to Allurion Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vicarious Surgical (RBOT) Competitors

RBOT vs. IINN, HIND, SURG, MBAI, and ALUR

How does Vicarious Surgical compare to Inspira Technologies OXY B.H.N.?

Which has stronger valuation and earnings, RBOT or IINN?

Is RBOT or IINN more profitable?

Do institutionals and insiders have more ownership in RBOT or IINN?

Does the media favor RBOT or IINN?

Do analysts rate RBOT or IINN?

Which has more volatility & risk, RBOT or IINN?

Summary

How does Vicarious Surgical compare to Vyome?

Which has stronger earnings and valuation, HIND or RBOT?

Is HIND or RBOT more profitable?

Does the media prefer HIND or RBOT?

Do insiders and institutionals have more ownership in HIND or RBOT?

Which has more risk and volatility, HIND or RBOT?

Do analysts rate HIND or RBOT?

Summary

How does Vicarious Surgical compare to SurgePays?

Which has more risk and volatility, SURG or RBOT?

Which has stronger valuation & earnings, SURG or RBOT?

Do institutionals & insiders hold more shares of SURG or RBOT?

Does the media refer more to SURG or RBOT?

Is SURG or RBOT more profitable?

Do analysts recommend SURG or RBOT?

Summary

How does Vicarious Surgical compare to Check-Cap?

Do institutionals & insiders have more ownership in RBOT or MBAI?

Does the media prefer RBOT or MBAI?

Is RBOT or MBAI more profitable?

Which has more volatility & risk, RBOT or MBAI?

Which has preferable earnings and valuation, RBOT or MBAI?

Do analysts recommend RBOT or MBAI?

Summary

How does Vicarious Surgical compare to Allurion Technologies?

Which has preferable earnings & valuation, RBOT or ALUR?

Is RBOT or ALUR more profitable?

Do insiders & institutionals believe in RBOT or ALUR?

Do analysts prefer RBOT or ALUR?

Which has more risk and volatility, RBOT or ALUR?

Does the media favor RBOT or ALUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools